AntibodystaleNational Cancer Institute (NCI)Phase 2
cixutumumab (cixutumumab)
Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer
#RecurrentNon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 11.1%임상시험 1상태 ACTIVE